Cabozantinib malate (XL184) is primarily used in the treatment of certain types of cancer. It is particularly effective in managing medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. The compound works by inhibiting multiple tyrosine kinases, which are enzymes involved in the growth and spread of cancer cells. This inhibition helps to slow down tumor growth and reduce the blood supply to the tumor, thereby limiting its ability to grow and metastasize. Additionally, cabozantinib malate is often used when other treatments have failed, providing a crucial option for patients with advanced or refractory disease. Its ability to target multiple pathways makes it a versatile agent in oncology, offering hope for improved outcomes in challenging cases.